Radiolabeled medication is widely used in the assessment of human ADME and also increasingly in assessing absolute bioavailability (BA). Conducting an ADME study early in the clinical development program—generally before or in parallel with Phase IIa—is prudent since the outcome may generate the need for additional toxicology studies.
We work with our sponsors to run diagnostic studies in a way that optimizes efficiency and ensures a positive and rewarding study experience for…
PRA Successfully Delivers A Complex Phase I Psoriasis Study
Exceptional Support and Innovative Strategies Combat Study Challenges.
Human Abuse Liability Studies: Not Your Traditional Phase I Study
Abuse potential refers to the likelihood for a drug to be used in nonmedical situations for its positive psychoactive effects. PRA Health Sciences’…